08 Jan 2026 | 5 Mins Read
India-made dengue vaccine completes Phase III trial enrolment
Flipitmoney
Panacea Biotec completed enrolment for its phase III clinical trial of DengiAll®, a tetravalent dengue vaccine candidate, with 10,335 participants across India. Enrolment was complete, marking a milestone in the development of India's first potential indigenous single-shot dengue vaccine, set to enter the market by 2027, subject to successful trial outcomes and regulatory approvals.